Abstract 【Objective】 To investigate the clinical effect of dexmedetomidine and midazolam on sedation in patients with severe tetanus. 【Methods】 A total of 64 patients with severe tetanus treated in Baoji People's Hospital from September 2018 to September 2020 were selected as the research object. According to the order of admission, they were divided into observation group and treatment group, with 32 cases in each group. The observation group was treated with human tetanus immunoglobulin combined with dexmedetomidine, and the control group was treated with human tetanus immunoglobulin combined with midazolam. The pulse oxygen saturation (SpO2), heart rate (HR), respiratory rate (RR) and mean arterial pressure (MAP) of the two groups were monitored before and 12 hours after treatment. The degree of sedation was evaluated by Ramsay score. The incidence of adverse reactions and mortality of the two groups were counted and compared. 【Results】 After 12 hours of treatment, SpO2 increased (P<0.05), HR, RR and MAP decreased (P<0.05), SpO2 in the observation group was higher than that in the control group (P<0.05), and HR, RR and MAP were lower than those in the control group (P<0.05).After 3 hours of treatment, the Ramsay score of the two groups was higher than that before treatment (P<0.05), but there was no significant difference between the two groups (P>0.05).The incidence of adverse reactions in the observation group was 6.25%, which was significantly lower than that in the observation group was 25.00%.The mortality of patients in the observation group was 3.13% (1/32), and there was no significant difference compared with 9.38% (3/32) in the group B (Fisher exact test,P=0.613). 【Conclusion】 For patients with severe tetanus, the application of human tetanus immunoglobulin combined with dexmedetomidine can achieve good sedative effect, improve SpO2, HR, RR and MAP, and have less adverse reactions.
FENG Yi-fan,LIU Kang. Clinical Study on Sedative Effect of Dexmedetomidine and Midazolam in Patients with Severe Tetanus[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 709-712.
[1] 王传林,刘斯,邵祝军,等.外伤后破伤风疫苗和被动免疫制剂使用指南[J].中国疫苗和免疫,2020,26(1):111-115.
[2] 张晓萌,王艳华,王传林.成人重症破伤风的诊断与治疗[J].中国急救复苏与灾害医学杂志,2018,13(11):1087-1093.
[3] 黄志聪,成石阳,罗海杰.破伤风人免疫球蛋白与马血清破伤风抗毒素的使用比较[J].深圳中西医结合杂志,2020,30(12):137-139.
[4] MORETTI R, JULLIAND S, RINALDI V E,et al.Buccal midazolam compared with rectal diazepam reduces seizure duration in children in the outpatient setting[J].Pediatr Emerg Care,2019,35(11):760-764.
[5] TEIK E O,HUTCHINSON R,SHORT S,et al.Verification of the acute physiology and chronic health evaluation scoring system in a Hong Kong intensive care unit[J].Crit Care Med,1993,21(5):698-705.
[6] 中国医师协会急诊医师分会,中国人民解放军急救医学专业委员会,北京急诊医学学会, 等.成人破伤风急诊预防及诊疗专家共识[J].解放军医学杂志,2018,43(12):991-1001.
[7] 郭鹏,刘菊,王刚,等.纳布啡复合舒芬太尼不同剂量组合用于腹式子宫切除术后镇痛的观察[J].中国医师进修杂志,2019,42(7):603-607.
[8] 梁贤栋.早期气管切开联合应用高剂量镇静等综合治疗重症破伤风的临床疗效分析[J].现代诊断与治疗,2020,31(19):3067-3069.
[9] 秦浩,吴凤影,魏金刚.五虎追风散配合咪达唑仑治疗重症破伤风患者痉挛的临床效果与安全性分析[J].世界中西医结合杂志,2019,14(2):250-253.
[10] 王益斐,徐文鸿,李国法,等.以右美托咪定为基础早期目标导向镇静策略对脓毒症患者胃肠功能的影响[J].中华重症医学电子杂志(网络版),2019,5(4):317-324.
[11] 杜秀玉,翟晓东,刘志,等.芬太尼联合咪达唑仑镇痛镇静在神经外科重症患者改良经皮气管切开中的应用效果[J].中国医药导报,2020,17(16):109-111.
[12] 赵千文,吴海华,谢玉萍.舒芬太尼联合咪达唑仑对机械通气脓毒症患者镇静效果及炎症因子的影响[J].临床肺科杂志,2019,24(8):1446-1449.
[13] 肖骏,李德科.舒芬太尼联合咪达唑仑对颅脑损伤患者的镇静镇痛效果及安全性分析[J].解放军医药杂志,2018,30(3):66-69.
[14] 唐志红,李娜,许静,等.重症监护室重症病人采用右美托咪定和咪达唑仑镇静治疗的有效性和安全性的Meta分析[J].安徽医药,2020,24(3):534-540.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 768-770.
2022, Vol. 39 
